Zepbound's huge success is largely why investors are bullish on the business, and why it looks unstoppable. And as the company works on oral drugs and other weight loss treatments, it could unlock ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a big revenue ... is essential to our mission of empowering investor success. We provide a platform for our authors to ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage study of its investigational candidate, amycretin, in overweight/obese ...

Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...

GLP-1 drugs Mounjaro and Zepbound drive a big revenue increase ... freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on ...

"Short of guaranteeing success, which they can't do because they ... to plan ahead for this year. Lilly's Zepbound and Novo's Wegovy dominate a market for weight-loss treatments that analysts ...